pembrolizumab based treatment (n=-9) vs. chemotherapy (n=-9)
randomized controlled trial
pembrolizumab plus docetaxel
200 mg of pembrolizumab every 3 weeks for up to approximately 2 years plus 75 mg/m2 of docetaxel and 5 mg of prednisone twice daily for approximately 7 months
docetaxel alone
placebo plus docetaxel and prednisone on the same schedule
on day 1 of each 3-week cycle, patients received 8 mg of oral dexamethasone at 12 hours, 3 hours, and 1 hour prior to docetaxel administration
metastatic (mCRPC) - 1st line (L1)
patients with mCRPC who had not received chemotherapy for mCRPC but whose disease had progressed on or was intolerant to a next-generation hormonal agent
double-blind
Pembrolizumab Plus Chemotherapy Fails to Improve OS, Radiographic PFS